4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.88 Average PT from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $29.8750.

A number of research firms have recently weighed in on FDMT. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. Royal Bank Of Canada boosted their price target on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. Finally, Chardan Capital reiterated a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th.

4D Molecular Therapeutics Stock Down 1.0%

NASDAQ FDMT opened at $8.60 on Friday. 4D Molecular Therapeutics has a fifty-two week low of $3.37 and a fifty-two week high of $12.34. The stock has a market cap of $449.61 million, a price-to-earnings ratio of -3.35 and a beta of 2.77. The business has a fifty day moving average of $9.46 and a 200-day moving average of $9.36.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The company had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. As a group, analysts anticipate that 4D Molecular Therapeutics will post -3.77 EPS for the current year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several institutional investors have recently added to or reduced their stakes in FDMT. Janus Henderson Group PLC increased its stake in 4D Molecular Therapeutics by 164.4% in the fourth quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock valued at $34,726,000 after purchasing an additional 2,882,508 shares during the last quarter. State Street Corp increased its stake in 4D Molecular Therapeutics by 197.5% in the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after purchasing an additional 1,785,106 shares during the last quarter. RA Capital Management L.P. increased its stake in 4D Molecular Therapeutics by 23.9% in the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after purchasing an additional 1,090,000 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in 4D Molecular Therapeutics by 605.8% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock valued at $9,264,000 after purchasing an additional 1,060,156 shares during the last quarter. Finally, Evergreen Quality Fund GP Ltd. acquired a new position in 4D Molecular Therapeutics in the fourth quarter valued at $7,136,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.